HCAR2 and metabolic syndrome: Accordingly, after the deorphanization, all major pharmaceutical companies and many biotech companies started large campaigns to develop novel GPR109A agonists, hoping to obtain more efficacious dyslipidemia drugs with fewer side effects30.